PrediSurge Company Profile

Background

Overview

PrediSurge, founded in May 2017 in Saint-Étienne, France, is a medtech company specializing in predictive software solutions for cardiovascular interventions. The company emerged as a spin-off from the biomedical laboratory of Mines Saint-Étienne, focusing on enhancing the safety and efficacy of minimally invasive cardiovascular procedures through advanced digital technologies.

Mission and Vision

PrediSurge's mission is to revolutionize cardiovascular care by providing physicians and medtech companies with innovative tools that improve procedure planning and medical device design. The company's vision is to digitalize cardiovascular healthcare, aiming to change the lives of millions of patients by offering personalized predictive simulations that enhance clinical outcomes.

Primary Area of Focus

The company's primary focus is on developing precision medicine platforms that assist in planning endovascular interventions. By creating patient-specific digital twins—numerical models simulating the biomechanical behavior of arteries and valves—PrediSurge enables clinicians to predict and prevent post-operative complications, thereby improving patient outcomes.

Industry Significance

PrediSurge holds a significant position in the medtech industry by pioneering the application of digital twin technology in cardiovascular interventions. This innovation addresses critical challenges in procedure planning and device design, offering a cost-effective solution to test multiple medical device designs at every stage of the development process.

Key Strategic Focus

Core Objectives

• Enhancing Procedure Planning: Developing tools that allow for precise simulation of endovascular interventions, leading to improved surgical outcomes.

• Medical Device Optimization: Providing medtech companies with numerical tools to refine device designs, ensuring better fit and function within patient-specific anatomies.

Specific Areas of Specialization

• Digital Twin Technology: Utilizing advanced computational modeling to create virtual replicas of patients' cardiovascular systems.

• Predictive Simulations: Employing simulations to assess the biomechanical behavior of arteries and valves, aiding in pre-operative planning.

Key Technologies Utilized

• Artificial Intelligence (AI): Integrating AI algorithms to enhance the accuracy and predictive capabilities of simulations.

• Numerical Simulation: Applying complex mathematical models to simulate surgical interventions and predict outcomes.

Primary Markets Targeted

• Clinical Centers: Providing tools for hospitals and clinics to plan and execute cardiovascular procedures with higher precision.

• Medical Device Manufacturers: Collaborating to design and test devices that are tailored to individual patient anatomies.

Financials and Funding

Funding History

Since its inception, PrediSurge has secured significant funding to support its growth and technological advancements.

Total Funds Raised

• €1.5 Million Seed Round (2020): Initial funding to establish and develop the company's technology.

• €2.5 Million Grant from the European Innovation Council (EIC) (March 2022): Non-repayable funding to support the development of innovative projects.

• €6.5 Million Series A Funding (October 2023): Led by LIFTT S.p.A., with participation from the EIC Fund, Saint Victor Capital, UI Investissement – Metropoles Innovations, and Crédit Agricole LHL Capital Innovation. This round included €4 million in capital.

Utilization of Capital

The funds have been allocated to:

• International Expansion: Extending the company's reach to leading cardiovascular device manufacturers worldwide.

• Product Industrialization: Scaling the PlanOp™ platform and associated processes to meet increasing demand.

• Research and Development: Enhancing existing products and exploring new segments within the vascular and structural heart domains.

Pipeline Development

Key Pipeline Candidates

PrediSurge's flagship product is the PlanOp™ platform, a CE-marked software that utilizes pre-operative imaging to create numerical models simulating the biomechanical behavior of arteries and valves, generating patient-specific digital twins.

Stages of Development

• Clinical Validation: Conducting studies to validate the accuracy and effectiveness of the digital twin simulations.

• Regulatory Compliance: Achieving CE certification to ensure compliance with European medical device regulations.

Target Conditions

• Aortic Aneurysms: Improving planning and outcomes of endovascular aneurysm repair (EVAR) procedures.

• Structural Heart Diseases: Enhancing interventions for conditions such as mitral valve repair.

Anticipated Milestones

• Product Launches: Introducing enhanced versions of PlanOp™ to broader markets.

• Regulatory Approvals: Securing additional certifications for international markets.

Technological Platform and Innovation

Proprietary Technologies

• Digital Twin Technology: Creating virtual replicas of patients' cardiovascular systems to simulate and predict surgical outcomes.

• Predictive Simulation Algorithms: Utilizing advanced computational models to assess the biomechanical behavior of arteries and valves.

Significant Scientific Methods

• Numerical Simulation: Employing complex mathematical models to simulate surgical interventions and predict outcomes.

• Artificial Intelligence (AI): Integrating AI algorithms to enhance the accuracy and predictive capabilities of simulations.

Leadership Team

Key Executives

• Bruno Virieux (CEO): With a background in engineering and business development, Bruno has been instrumental in leading PrediSurge's strategic direction and growth.

• Jean-Noël Albertini (Co-founder): A cardiologist with extensive experience in cardiovascular interventions, Jean-Noël has contributed significantly to the clinical validation and application of PrediSurge's technology.

• David Perrin (Co-founder): An engineer specializing in biomedical applications, David has played a key role in the development of the company's digital twin technology.

Leadership Changes

As of the latest available information, there have been no significant changes or appointments within the company's leadership.

Competitive Landscape

Market Insights and Dynamics

The digital twin in healthcare market is experiencing rapid growth, driven by the increasing demand for personalized therapies and advancements in AI and machine learning technologies. PrediSurge competes with other companies in this space, including Atos SE, Microsoft, Koninklijke Philips N.V., Unlearn.ai, QiO Technologies, VERTO, Dassault Systèmes, ThoughtWire, Faststream Technologies, and Twin Health.

Competitor Analysis

• Atos SE: A global leader in digital transformation, offering digital twin solutions across various industries, including healthcare.

• Microsoft: Provides cloud-based digital twin platforms with applications in healthcare, enabling real-time monitoring and predictive analytics.

• Koninklijke Philips N.V.: Offers healthcare solutions incorporating digital twin technology for patient monitoring and personalized treatment planning.

• Unlearn.ai: Specializes in AI-driven digital twin technology for clinical trials, aiming to reduce the time and cost of drug development.

• QiO Technologies: Provides AI-powered digital twin solutions for industrial applications, including healthcare.

• VERTO: Offers digital twin technology for healthcare facilities, focusing on operational efficiency and patient care optimization.

• Dassault Systèmes: Develops 3D design and simulation software, including digital twin solutions for healthcare applications.

• ThoughtWire: Provides digital twin technology for smart hospitals, aiming to improve patient outcomes and operational efficiency.

• Faststream Technologies: Offers digital twin solutions for healthcare, focusing on patient monitoring and predictive analytics.

• Twin Health: Specializes in digital twin technology for metabolic health, providing personalized treatment plans.

Strategic Collaborations and Partnerships

PrediSurge has established significant collaborations to enhance its market position:

• Medtronic: In November 2024, PrediSurge announced a collaboration with Medtronic to integrate its AI-powered digital twin technology with Medtronic's Endurant™ stent graft, resulting in the SmartPlan Pro service designed to provide enhanced planning accuracy and reliability for endovascular aortic interventions.

Operational Insights

PrediSurge differentiates itself through its specialized focus on cardiovascular interventions, leveraging digital twin technology to provide personalized predictive simulations. This approach offers a unique value proposition in the medtech industry, setting it apart from competitors that may offer broader digital twin solutions without the same level of specialization.